Given the abundant presence of nucleic acids at the tumor site, released by tumor cells dying by constitutive or chemotherapy-induced apoptosis, TIM-3 can be viewed as a new promising target for anticancer therapeutic settings to improve vaccination protocols involving nucleic acids. This evidence concerns the gene HAVCR2 and neoplasm.